FDA approves infant combo vaccine for meningitis

June 14, 2012

(AP) — The first vaccine that protects children as young as six weeks against two potentially deadly bacterial infections has won approval from U.S. health regulators.

The Food and Drug Administration approved Menhibrix, a combination vaccine for infants and babies that prevents meningococcal disease and haemophilus influenza. Those bacteria can cause potentially deadly illness, or lead to blindness, mental retardation and amputation.

The FDA said the diseases are difficult to spot because their symptoms are similar to the common cold.

The vaccine is given in a four-dose regimen beginning as early as six weeks of age. The fourth dose can be given as late as 18 months of age.

The is manufactured by GlaxoSmithKline PLC at facilities in Belgium.

Explore further: FDA expands meningitis vaccine age range

shares

Related Stories

FDA expands meningitis vaccine approval

October 22, 2007

The U.S. Food and Drug Administration has expanded approval for the use of Menactra, a bacterial meningitis vaccine, to children ages 2 to 10.

Sanofi gets expanded meningitis vaccine approval

April 25, 2011

(AP) -- Sanofi Pasteur, the vaccines division of Sanofi-Aventis, said Monday the Food and Drug Administration approved the company's bacterial meningitis vaccine Menactra for children between the ages of 9 months and 23 months.

FDA approves first 4-in-1 flu vaccine

February 29, 2012

Federal health officials have approved the first vaccine that protects against four strains of the common flu, offering one additional layer of protection against the influenza virus that affects millions each year.

Recommended for you

Non-addictive painkiller shows promise in animal trials

August 30, 2016

(HealthDay)—Preliminary research in monkeys suggests that a new medication might be able to provide pain relief similar to opioid drugs such as OxyContin, but without the same potential for addiction or serious side effects.

Mylan launching cheaper, generic version of EpiPen

August 29, 2016

The maker of EpiPens will start selling a cheaper, generic version of the emergency allergy shots as the furor over repeated U.S. price hikes continues—and looming competition threatens its near-monopoly.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.